Collaborations & Alliances

Evotec Achieves €3M Sanofi Milestone

Meets criteria for a manufacturing process for generation of human induced pluripotent stem cell (iPSC)-derived beta cells

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Evotec AG has reached its second beta cell therapy milestone under its strategic alliance with Sanofi in the field of diabetes, triggering a €3 million payment to Evotec. Evotec met pre-agreed critical success criteria for a potential manufacturing process for generation of human induced pluripotent stem cell (iPSC)-derived beta cells, including the demonstration of upscaling potential and suitability of the cell product for encapsulated beta cell function in diabetes models. The goal of the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters